These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28321145)

  • 1. Drug Pricing Transparency: The New Retail Revolution.
    Dana KN; Hertig JB; Weber RJ
    Hosp Pharm; 2017 Feb; 52(2):155-159. PubMed ID: 28321145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. California's Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing.
    Gudiksen KL; Brown TT; Whaley CM; King JS
    Health Aff (Millwood); 2018 Sep; 37(9):1503-1508. PubMed ID: 30179546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Daniel K. Inouye College of Pharmacy Scripts: Prescription Drug Pricing.
    Sumida WK; Taniguchi R; Juarez DT
    Hawaii J Med Public Health; 2016 Jan; 75(1):25-30. PubMed ID: 26870605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of Retail Pricing of Generic Urologic Medications in a Major US Metropolitan Area.
    Xu PJ; Barnes JM; Choe EM; Syed JR; Siddiqui SA
    Urology; 2019 Mar; 125():29-33. PubMed ID: 30170089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managed health care.
    Curtiss FR
    Am J Hosp Pharm; 1989 Apr; 46(4):742-63. PubMed ID: 2719053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, and Total Spending for Diagnostic Tests.
    Robinson JC; Whaley C; Brown TT
    JAMA Intern Med; 2016 Sep; 176(9):1353-9. PubMed ID: 27454826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price transparency: building community trust.
    Clarke RL
    Front Health Serv Manage; 2007; 23(3):3-12. PubMed ID: 17405387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs.
    Ramsey SD
    Health Aff (Millwood); 2015 Apr; 34(4):571-5. PubMed ID: 25847638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in Europe.
    Carl DL; Vokinger KN
    Lancet Reg Health Eur; 2021 Apr; 3():100050. PubMed ID: 33899044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
    Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
    CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.